东莞证券股份有限公司 关于特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票 之 发行保荐书 保荐机构（主承销商） （注册地址：东莞市莞城区可园南路一号） 二〇二三年八月 特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票 发行保荐书 声 明 东莞证券股份有限公司（以下简称"保荐机构""本保荐机构""东莞证券"） 接受特一药业集团股份有限公司（以下简称"特一药业""公司"或"发行人"）的 委托，担任特一药业本次以简易程序向特定对象发行股票（以下简称"本项目"） 的保荐机构。 东莞证券及其保荐代表人根据《中华人民共和国公司法》（以下简称《公司 法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司证券发行注 册管理办法》（以下简称《注册管理办法》）、《证券发行上市保荐业务管理办法》 （以下简称《保荐业务管理办法》）、《发行证券的公司信息披露内容与格式准则 第 27 号——发行保荐书和发行保荐工作报告》等有关法律、法规和中国证监会 的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业 规范和道德准则出具发行保荐书，并保证所出具文件的真实性、准确性和完 ...

国浩律师（深圳）事务所 关于 特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票 的 法律意见书 深圳市福田区深南大道6008号特区报业大厦42、41、31DE、2403、2405 电话（Tel.）：(+86)(755)8351 5666 传真（Fax.）：(+86)(755)8351 5333/8351 5090 网站（Website）：http://www.grandall.com.cn 2023年8月 | 释 | 义 | | 2 | | --- | --- | --- | --- | | 第一节 | | 言 引 4 | | | 第二节 | | 正 文 6 | | | | | 一、本次发行的批准和授权 6 | | | | | 二、本次发行的主体资格 6 | | | | | 三、本次发行的实质条件 7 | | | | | 四、发行人的设立 | 11 | | | | 五、发行人的独立性 | 11 | | | | 六、发行人的主要股东（实际控制人） 12 | | | | | 七、发行人的股本及其演变 12 | | | | | 八、发行人的业务 12 | | | | | 九、关联交易及同业竞争 ...

东莞证券股份有限公司 关于特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票 之 上市保荐书 保荐机构（主承销商） （住所：东莞市莞城区可园南路一号） 二〇二三年八月 特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票 上市保荐书 声 明 东莞证券股份有限公司（以下简称"保荐机构""东莞证券"）接受特一药业 集团股份有限公司（以下简称"特一药业""公司"或"发行人"）的委托，担任特 一药业本次以简易程序向特定对象发行股票（以下简称"本项目"）的保荐机构。 保荐机构和保荐代表人已根据《中华人民共和国公司法》（以下简称《公 司法》）、《中华人民共和国证券法》（以下简称《证券法》）、《上市公司 证券发行注册管理办法》（以下简称《注册管理办法》）、《证券发行上市保 荐业务管理办法》（以下简称《保荐业务管理办法》）等法律法规和中国证券 监督管理委员会及深圳证券交易所的有关规定，诚实守信，勤勉尽责，严格按 照依法制定的业务规则和行业自律规范出具本上市保荐书，并保证所出具文件 真实、准确、完整。 本上市保荐书如无特别说明，相关用语具有与《特一药业集团股份有限公 司 2023 年度以简易程 ...

债券简称：特一转债 债券代码：128025 特一药业集团股份有限公司 （注册地址：台山市台城长兴路 9、11 号） 2023 年度以简易程序向特定对象发行股 票募集说明书 （申报稿） 保荐机构（主承销商） （注册地址：东莞市莞城区可园南路一号） 二〇二三年八月 股票简称：特一药业 股票代码：002728 特一药业集团股份有限公司 2023 年度以简易程序向特定对象发行股票募集说明书 发行人声明 本公司全体董事、监事、高级管理人员承诺募集说明书不存在任何虚假记 载、误导性陈述或重大遗漏，并保证所披露信息的真实、准确、完整。 本募集说明书按照《上市公司证券发行注册管理办法》《公开发行证券的 公司信息披露内容与格式准则第 61 号——上市公司向特定对象发行证券募集说 明书和发行情况报告书》等要求编制。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保 证募集说明书中财务数据真实、完整。 证券监督管理机构及其他政府部门对本次发行所作的任何决定，均不表明 其对发行人所发行证券的价值或者投资人的收益作出实质性判断或者保证。任 何与之相反的声明均属虚假不实陈述。 1-1-1 特一药业集团股份有限公司 202 ...

特一药业集团股份有限公司 审计报告及财务报表 二〇二二年度 V ( 特一药业集团股份有限公司 审计报告及财务报表 (2022年01月 01 日至 2022 年 12 月 31 日止) | | 目录 | 页次 | | | --- | --- | --- | --- | | . | 审计报告 | | 1-5 | | | 财务报表 | | | | | 合并资产负债表和母公司资产负债表 | | 1-4 | | | 合并利润表和母公司利润表 | | 5-6 | | | 合并现金流量表和母公司现金流量表 | | 7-8 | | | 合并所有者权益变动表和母公司所有者权益受灾灾 | | 9-12 | | | 财务报表附注 | | 1-84 | | 11 | 事务所执业资质证明 | | | 6-1-2 工信会计师事务所(特殊晋) AA SHU LUN PAN CERTIFIED I 审计报告 信会师报字[2023]第 ZI10259 号 信会师报字[2023]第 ZI10259 号 6-1-1 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（bttp://acc.nof.gov.cn）"进行" "打 进行食型 特一 ...

股票代码：002728 股票简称：特一药业 债券代码：128025 债券简称：特一转债 特一药业集团股份有限公司投资者关系活动记录表 编号：2023-004 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 ☑业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 通过"全景路演"(http://rs.p5w.net)参与业绩说明会的投资者 时间 2023 年 5 月 10 日 地点 公司二楼会议室 上市公司接待人 员姓名 董事长、总经理：许丹青 副董事长、副总经理：许松青 董事会秘书、财务负责人：陈习良 董事：卢北京 独立董事：曹艳铭 保荐代表人：郭文俊 投资者关系活动 主要内容介绍 一、请问公司业绩是不是出问题了，最近股价跌的很厉害 回复：您好！感谢您对公司的关注！公司的业绩情况详见公司的 2022 年年 报和 2023 年一季报。公司目前生产经营产销两旺。公司将继续努力把经营做得 更好，提升内功，夯实公司发展基础，提高股东回报，回馈投资者。二级市场 的股价波动，属于市场行为，受宏观经济、市场环境、投资偏好等多方面因素 影响，投资者在进 ...

| 股票代码：002728 | 股票简称：特一药业 | 公告编号：2023-033 | | --- | --- | --- | | 债券代码：128025 | 债券简称：特一转债 | | （问题征集专题页面二维码） 特此公告。 特一药业集团股份有限公司 关于举行 2022 年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特一药业集团股份有限公司定于 2023 年 5 月 10 日（周三）15:00-17:00 在全景网举 办 2022 年度业绩说明会，本次年度业绩说明会将采用网络远程的方式举行，投资者可 登陆全景网"投资者关系互动平台"（http://ir.p5w.net）参与本次年度业绩说明会。 出席本次说明会的人员有：公司董事长兼总经理许丹青先生、副董事长兼副总经理 许松青先生、财务负责人兼董事会秘书陈习良先生、董事卢北京先生、独立董事曹艳铭 女士、东莞证券保荐代表人郭文俊先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会提前向投 资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 ...

Financial Performance - The company's operating revenue for 2022 was CNY 886,570,938.60, representing a 16.94% increase compared to CNY 758,160,497.71 in 2021[20]. - The net profit attributable to shareholders for 2022 was CNY 178,204,104.28, a 40.41% increase from CNY 126,917,422.27 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 171,371,215.85, which is a 51.54% increase from CNY 113,083,086.36 in 2021[20]. - The net cash flow from operating activities was CNY 371,658,160.26, up 44.72% from CNY 256,814,750.48 in the previous year[20]. - The basic earnings per share for 2022 was CNY 0.80, reflecting a 29.03% increase from CNY 0.62 in 2021[20]. - Total assets at the end of 2022 amounted to CNY 2,545,604,654.93, a 23.20% increase from CNY 2,066,196,431.51 at the end of 2021[20]. - The net assets attributable to shareholders at the end of 2022 were CNY 1,403,139,439.55, an 11.21% increase from CNY 1,261,690,115.09 in 2021[20]. - The weighted average return on equity for 2022 was 13.98%, an increase of 2.38% from 11.60% in 2021[20]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of CNY 6.50 per 10 shares, along with a capital reserve increase of 4 shares for every 10 shares held[4]. - The total cash dividend amount for the reporting period is ¥159,514,247.75, which represents 36.34% of the total distributable profit of ¥438,924,757.50[163][160]. - The proposed cash dividend distribution is ¥6.50 per 10 shares (including tax), along with a capital reserve increase of 4 shares for every 10 shares held[162][163]. - The company's profit distribution policy cannot be changed arbitrarily and must be approved by the board and shareholders if adjustments are necessary due to operational conflicts[157]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a shift towards high-quality development, providing opportunities for the company amidst ongoing reforms[29]. - The aging population in China reached 19.8% by the end of 2022, increasing the demand for pharmaceutical products and services[32]. - The company is navigating a complex competitive landscape in the pharmaceutical industry, which presents both challenges and opportunities for growth[32]. Product Development and R&D - The company focuses on the research, production, and sales of traditional Chinese medicine and chemical drugs, positioning itself strategically in the healthcare sector[33]. - The company has 31 invention patents, 33 design patents, and 8 utility model patents as of the end of the reporting period[39]. - Research and development expenses for 2022 were ¥38,009,796.53, a slight increase of 0.62% compared to 2021[62]. - The company has initiated clinical trials for the Skin Disease Blood Detox Pill, aiming to enhance its product portfolio[40]. - The company is committed to the innovation and development of traditional Chinese medicine, aligning with national policies to promote its growth[96]. Sales and Marketing Strategy - The company plans to shift from a distributor model to direct sales to retail terminals to enhance marketing channel effectiveness[38]. - The company’s marketing strategy has been adjusted to increase market expansion and promotional efforts, leading to improved sales performance[42]. - The company aims to enhance marketing capabilities and expand the market share of "Zhi Ke Bao Pian" by deepening existing markets and exploring new ones[98]. Environmental Compliance and Sustainability - The company has made continuous investments in environmental protection to reduce resource consumption and pollution[184]. - The company has a wastewater treatment capacity of 240 tons per day, achieving surface IV class standards for treated wastewater[185]. - The company has obtained pollution discharge permits for its subsidiaries, with validity extending until 2026 and 2027[181]. - The company emphasizes employee rights protection, adhering to labor laws and engaging employees in decision-making processes[195]. Governance and Shareholder Rights - The company maintains complete independence from its controlling shareholder in terms of assets, personnel, finance, organization, and business operations[126]. - The company actively expands communication channels with investors to ensure fair and timely information disclosure, maintaining the rights of shareholders and stakeholders[126]. - The company has established a performance evaluation system for senior management, ensuring that compensation reflects job responsibilities and performance[170]. Future Outlook and Guidance - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming to reach 1.875 billion[114]. - The company is exploring potential acquisitions to strengthen its portfolio, with a budget of up to 200 million allocated for this purpose[114]. - The overall market outlook remains positive, with anticipated growth driven by increasing demand for healthcare products and services[114].

Financial Performance - The company's revenue for Q1 2023 reached ¥304,157,421.18, representing a 56.50% increase compared to ¥194,348,090.18 in the same period last year[3] - Net profit attributable to shareholders was ¥105,470,920.94, a significant increase of 130.96% from ¥45,666,688.38 year-on-year[3] - Basic earnings per share rose to ¥0.46, up 119.05% from ¥0.21 in the previous year[3] - Operating profit for the quarter was CNY 127,043,924.70, compared to CNY 54,538,015.75 in Q1 2022, marking an increase of 133.3%[15] - The company’s total comprehensive income for the quarter was CNY 105,470,920.94, up from CNY 45,666,688.38 in the same period last year, indicating a growth of 131.3%[16] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,498,981,899.98, a decrease of 1.83% from ¥2,545,604,654.93 at the end of the previous year[3] - Cash and cash equivalents at the end of Q1 2023 totaled ¥700,881,200.19, down from ¥739,660,362.06 at the beginning of the year[10] - Total assets as of March 31, 2023, were ¥2,498,981,899.98, a decrease from ¥2,545,604,654.93 at the beginning of the year[12] - Total liabilities decreased to ¥989,721,619.89 from ¥1,142,465,215.38 at the start of the year[12] - The company's equity attributable to shareholders increased to ¥1,509,260,280.09, up from ¥1,403,139,439.55 at the beginning of the year[12] Cash Flow - The company reported a net cash flow from operating activities of ¥26,912,422.14, slightly up by 1.02% from ¥26,640,062.41[3] - Cash flow from operating activities generated a net inflow of CNY 26,912,422.14, slightly up from CNY 26,640,062.41 in the previous year[16] - The net cash outflow from investing activities was CNY -19,235,255.51, compared to CNY -63,112,412.77 in the same period last year[17] - Cash inflow from financing activities totaled CNY 63,918,749.00, a decrease from CNY 229,000,000.00 in Q1 2022[17] Costs and Expenses - Total operating costs for Q1 2023 were ¥180,960,104.90, up 29.2% from ¥140,109,023.79 in Q1 2022[14] - Research and development expenses increased to ¥10,182,147.51, reflecting a rise of 17.7% from ¥8,650,287.50 in the previous year[14] - The company incurred a tax expense of CNY 21,553,510.03, compared to CNY 8,718,235.87 in the previous year, reflecting a growth of 147.0%[15] Market and Growth Strategy - The increase in revenue was primarily driven by a significant rise in pharmaceutical sales, contributing to a gross profit margin increase[5] - The company plans to continue expanding its market presence and investing in new product development to sustain growth[5] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[11] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 67,464, with the largest shareholder holding 31.16% of the shares[7]

Group 1: Company Overview - The company is named Te Yi Pharmaceutical Group Co., Ltd., previously known as Tai Cheng Pharmaceutical [1][12] - The company held an investor relations activity on April 11, 2017, to discuss performance [1] Group 2: Financial Plans and Performance - The company plans to issue convertible bonds, pending shareholder approval [2] - As of December 31, 2016, the company had a total debt of ¥716.61 million and paid ¥17.33 million in interest for the year [7] - The net profit for 2016 was ¥94.78 million, representing a year-on-year growth of 16.86% [11][12] Group 3: Market Position and Sales - Major sales regions include South China (¥276 million, 42.04% of total sales), East China (¥118 million, 18.02%), Northeast (¥68 million, 10.37%), and Central China (¥61 million, 9.27%) [9] - The company maintains stable relationships with its top customers [10] Group 4: Industry Challenges and Opportunities - The company faces challenges due to increased regulation on drug prices and quality, but this also presents opportunities for stronger companies [3] - The company is considering mergers and acquisitions to enhance competitiveness and risk resistance [4] Group 5: Innovation and Development - The company has not established plans for a merger fund but is open to future opportunities [2] - There are no current plans to explore new fields outside the pharmaceutical industry [6] Group 6: Investor Relations and Shareholder Returns - The company aims to continuously reward shareholders through dividends and other means within regulatory frameworks [8] - The company is committed to improving its market value management and enhancing shareholder returns [10]